Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025MedScienOpen Access

Can Targeted Drugs Developed from the Study of Human Endogenous Retrovirus K Replace Traditional Chemotherapy in terms of Colorectal Tumors?

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJiahe Yu

Discussion

Loading...

Member takes

Overview

Analysis reveals HERV-K-targeted therapies may improve outcomes in colorectal cancer, suggesting a shift from traditional chemotherapy.

Key Points

  • Targeted therapies using human endogenous retrovirus K show promise in treating colorectal cancer, emphasizing an innovative approach.
  • Efficacy comparisons indicate that HERV-K-targeted strategies may reduce side effects commonly associated with traditional chemotherapy.
  • The review integrates literature on HERV-K's role in carcinogenesis and therapeutic advancements like CRISPR and immune therapies.
  • While potential exists, HERV-K therapies currently face development challenges, including high costs and limited clinical trials.

Cite This Study

Jiahe Yu (2025) studied this question.

synapsesocial.com/papers/68af7c8d7567bf4f94ff3f31https://doi.org/10.61173/27xe3f16
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions2025 · 7 citations
  2. 2CRISPR Gene Editing Strategies for Targeting Oncogene Addiction in Colorectal Cancer2025
  3. 3The expression, regulation, and function of human endogenous retroviruses in genitourinary cancers2025
  4. 4Co-Targeting KRASG12D and the HER family is efficacious in colorectal cancer2025
  5. 5Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations2025